Tamoxifen evolution

Howell, Anthony; Howell, Sacha J.

doi:10.1038/s41416-023-02158-5

Cited by 33 publications

(26 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAM represents the pioneering targeted drug for both the treatment and prevention of breast cancer and is extensively employed in clinical practice for managing patients with ER‐positive breast cancer. It can significantly reduce patient recurrence rates and mortality 115,116 . Research has shown that autophagy is a potential mechanism of TAM drug resistance and overexpressing Beclin 1, a key autophagy player, can promote TAM drug resistance.…”

Section: Lncrna Participates In the Generation Of Anti‐cancer Drug Re...mentioning

confidence: 99%

H1Innovative approaches to combat anti‐cancer drug resistance: Targeting lncRNA and autophagy

Zhong,

Xie,

Duan

2023

Clinical & Translational Med

View full text Add to dashboard Cite

BackgroundTo date, standardizing clinical predictive biomarkers for assessing the response to immunotherapy remains challenging due to variations in personal genetic signatures, tumour microenvironment complexities and epigenetic onco‐mechanisms.Main BodyEarly monitoring of key non‐coding RNA (ncRNA) biomarkers may help in predicting the clinical efficacy of cancer immunotherapy and come up with standard predictive ncRNA biomarkers. For instance, reduced miR‐125b‐5p level in the plasma of non‐small cell lung cancer patients treated with anti‐PD‐1 predicts a positive outcome. The level of miR‐153 in the plasma of colorectal cancer patients treated with chimeric antigen receptor T lymphocyte (CAR‐T) cell therapy may indicate the activation of T‐cell killing activity. miR‐148a‐3p and miR‐375 levels may forecast favourable responses to CAR‐T‐cell therapy in B‐cell acute lymphoblastic leukaemia. In cancer patients treated with the GPC3 peptide vaccine, serum levels of miR‐1228‐5p, miR‐193a‐5p and miR‐375‐3p were reported as predictive biomarkers of good response and improved overall survival. Therefore, there is a critical need for further studies to elaborate on the key ncRNA biomarkers that have the potential to predict early clinical responses to immunotherapy.ConclusionsThis review summarises important predictive ncRNA biomarkers that were reported in cancer patients treated with different immunotherapeutic modalities including monoclonal antibodies, small molecule inhibitors, cancer vaccines and CAR‐T cells. In addition, a concise discussion on forthcoming perspectives is provided, outlining technical approaches for the optimal utilisation of immune‐modulatory ncRNA biomarkers as predictive tools and therapeutic targets.

show abstract

Section: Lncrna Participates In the Generation Of Anti‐cancer Drug Re...mentioning

confidence: 99%

H1Innovative approaches to combat anti‐cancer drug resistance: Targeting lncRNA and autophagy

Zhong,

Xie,

Duan

2023

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…1 Superficial fungal infections such as ringworm, mucosal, and vaginal infections account for 15% of fungal infections, thereby making them the most deadly among other communicable diseases. 2,3 Innate immunity, also called the first line of defence, caused by the body surface and epithelial surfaces of the respiratory, genitourinary, and gastrointestinal tracts, acts as a barrier against fungi. 4 Cells of innate response like neutrophils and dendritic cells can cause direct antifungal effects or can secrete microbicidal compounds to clear fungal infections.…”

Section: Introductionmentioning

confidence: 99%

Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance

Mehta¹,

Saini²,

Bajaj³

2023

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

“…[5][6] Tamoxifen, an estrogen receptor alpha (ER-α) antagonist, is often recommended to treat breast cancer. [7] In a number of in vitro investigations, elevated levels of estrogen receptors were found on melanoma cells that originated from metastatic tumors. [8] ER-α, in particular, promotes cell growth and cellular atypia.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues

Urbaniak,

Bathula,

Chauhan

et al. 2023

Chemistry & Biodiversity

View full text Add to dashboard Cite

A major challenge for clinical management of melanoma is the prevention and treatment of metastatic disease. Drug discovery efforts over the last 10 years have resulted in several drugs that improve the prognosis of metastatic melanoma; however, most patients develop early resistance to these treatments. We designed and synthesized, through a concise synthetic strategy, a series of hybrid olefin‐pyridinone compounds that consist of structural motifs from tamoxifen and ilicicolin H. These compounds were tested against a human melanoma cell line and patient‐derived melanoma cells that had metastasized to the brain. Three compounds 7 b, 7 c, and 7 g demonstrated promising activity (IC50=0.4–4.3 μM). Cell cycle analysis demonstrated that 7 b and 7 c induce cell cycle arrest predominantly in the G1 phase. Both 7 b and 7c significantly inhibited migration of A375 melanoma cells; greater effects were demonstrated by 7 b. Molecular modelling analysis provides insight into a plausible mechanism of action.

show abstract

Tamoxifen evolution

Cited by 33 publications

References 67 publications

H1Innovative approaches to combat anti‐cancer drug resistance: Targeting lncRNA and autophagy

H1Innovative approaches to combat anti‐cancer drug resistance: Targeting lncRNA and autophagy

Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance

Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues

Contact Info

Product

Resources

About